1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (617) 632-2165
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
Article first published online: 21 JUL 2006
DOI: 10.1002/cncr.22085
Copyright © 2006 American Cancer Society
Additional Information
How to Cite
Nakabayashi, M., Xie, W., Regan, M. M., Jackman, D. M., Kantoff, P. W. and Oh, W. K. (2006), Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer, 107: 975–981. doi: 10.1002/cncr.22085
Publication History
- Issue published online: 21 AUG 2006
- Article first published online: 21 JUL 2006
- Manuscript Accepted: 9 MAY 2006
- Manuscript Revised: 12 APR 2006
- Manuscript Received: 9 FEB 2006
Funded by
- C. Brendan Noonan Charitable Foundation
- Bing Sound Wong Fund for Prostate Cancer Research
REFERENCES
- 1, . Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998; 160: 1220–1229.
- 2. Secondary hormonal therapies in the treatment of prostate cancer. Urology. 2002; 60: 87–92; discussion 93.
- 3, , , et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–1512.
- 4, , , et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513–1520.
- 5. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987; 317: 812–818.
- 6, , , et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982; 97: 370–372.
- 7, , , et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982; 142: 2137–2140.
- 8, , . Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol. 1983; 130: 152–153.
- 9, . Ketoconazole therapy for advanced prostate cancer. Lancet. 1984; 2: 433–435.
- 10, , , et al. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol. 1986; 58: 45–51.Direct Link:
- 11, , , et al. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol. 1989; 7: 1093–1098.
- 12, , , et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004; 22: 1025–1033.
- 13, , , et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002; 168: 542–545.
- 14, , , et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461–3467.
- 15, , , et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997; 157: 1204–1207.
- 16, , , et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol. 2005; 173: 1947–1952.
- 17, , , et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol. 2005; 173: 790–796.
- 18, , , et al. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother. 1980; 6: 552–554.
- 19, , , et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999; 17: 2506–2513.
- 20, . Inhibition by ketoconazole of mitogen-induced DNA synthesis and cholesterol biosynthesis in lymphocytes. Antimicrob Agents Chemother. 1983; 24: 478–485.
- 21, , . Effects of ketoconazole on rat ovarian steroidogenic enzymatic activities. Res Commun Chem Pathol Pharmacol. 1986; 52: 403–406.
- 22, , , et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983; 71: 1495–1499.
- 23, . Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab Dispos. 1984; 12: 603–606.
- 24, , , et al. In vivo and in vitro inhibition of hepatic microsomal drug metabolism by ketoconazole. Br J Exp Pathol. 1985; 66: 737–742.
- 25, , , et al. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983; 57: 732–736.
- 26. Ketoconazole-induced stimulation of gonadotropin output in men: basis for a potential test of gonadotropin reserve. J Clin Endocrinol Metab. 1986; 63: 1121–1125.